Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2008

Open Access 01-12-2008 | Research article

A human monoclonal autoantibody to breast cancer identifies the PDZ domain containing protein GIPC1 as a novel breast cancer-associated antigen

Authors: Sergei Rudchenko, Matthew Scanlan, Gavreel Kalantarov, Victoria Yavelsky, Chen Levy, Alison Estabrook, Lloyd Old, Gerald L Chan, Leslie Lobel, Ilya Trakht

Published in: BMC Cancer | Issue 1/2008

Login to get access

Abstract

Background

We have been studying the native autoimmune response to cancer through the isolation of human monoclonal antibodies that are cancer specific from cancer patients. To facilitate this work we previously developed a fusion partner cell line for human lymphocytes, MFP-2, that fuses efficiently with both human lymph node lymphocytes and peripheral blood lymphocytes. Using this unique trioma fusion partner cell line we isolated a panel of autologous human monoclonal antibodies, from both peripheral blood and lymph node lymphocytes, which are representative of the native repertoire of anti-cancer specific antibodies from breast cancer patients.

Methods

The current study employs immunocytochemistry, immunohistochemistry, Western blot analysis as well as Northern blots, Scatchard binding studies and finally SEREX analysis for target antigen identification.

Results

By application of an expression cloning technique known as SEREX, we determined that the target antigen for two monoclonal antibodies, 27.B1 and 27.F7, derived from lymph node B-cells of a breast cancer patient, is the PDZ domain-containing protein known as GIPC1. This protein is highly expressed not only in cultured human breast cancer cells, but also in primary and metastatic tumor tissues and its overexpression appears to be cancer cell specific. Confocal microscopy revealed cell membrane and cytoplasmic localization of the target protein, which is consistent with previous studies of this protein.

Conclusion

We have determined that GIPC1 is a novel breast cancer-associated immunogenic antigen that is overexpressed in breast cancer. Its role, however, in the initiation and/or progression of breast cancer remains unclear and needs further clarification.
Appendix
Available only for authorised users
Literature
1.
Spadaro M, Lanzardo S, Curcio C, Forni G, Cavallo F: Immunological inhibition of carcinogenesis. Cancer Immunol Immunother. 2004, 53 (3): 204-216.CrossRefPubMed
2.
Pardoll D: Does the immune system see tumors as foreign or self?. Annu Rev Immunol. 2003, 21: 807-839.CrossRefPubMed
3.
Drake CG, Jaffee E, Pardoll DM: Mechanisms of immune evasion by tumors. Adv Immunol. 2006, 90: 51-81.CrossRefPubMed
4.
Adair SJ, Carr TM, Fink MJ, Slingluff CL, Hogan KT: The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes. J Immunother. 2008, 31 (1): 7-17.CrossRefPubMed
5.
Akcakanat A, Kanda T, Koyama Y, Watanabe M, Kimura E, Yoshida Y, Komukai S, Nakagawa S, Odani S, Fujii H, Hatakeyama K: NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer. Cancer Chemother Pharmacol. 2004, 54 (1): 95-100.CrossRefPubMed
6.
Fossa A, Berner A, Fossa SD, Hernes E, Gaudernack G, Smeland EB: NY-ESO-1 protein expression and humoral immune responses in prostate cancer. Prostate. 2004, 59 (4): 440-447.CrossRefPubMed
7.
Jager E, Jager D, Knuth A: Strategies for the development of vaccines to treat breast cancer. Recent Results Cancer Res. 1998, 152: 94-102.CrossRefPubMed
8.
Knuth A, Jager D, Jager E: Cancer immunotherapy in clinical oncology. Cancer Chemother Pharmacol. 2000, 46 Suppl: S46-51.CrossRefPubMed
9.
Korangy F, Ormandy LA, Bleck JS, Klempnauer J, Wilkens L, Manns MP, Greten TF: Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res. 2004, 10 (13): 4332-4341.CrossRefPubMed
10.
Parmigiani RB, Bettoni F, Grosso DM, Lopes A, Cunha IW, Soares FA, Carvalho AL, Fonseca F, Camargo AA: Antibodies against the cancer-testis antigen CTSP-1 are frequently found in prostate cancer patients and are an independent prognostic factor for biochemical-recurrence. Int J Cancer. 2008, 122 (10): 2385-90.CrossRefPubMed
11.
McDermott RS, Beuvon F, Pauly M, Pallud C, Vincent-Salomon A, Mosseri V, Pouillart P, Scholl SM: Tumor antigens and antigen-presenting capacity in breast cancer. Pathobiology. 2002, 70 (6): 324-332.CrossRefPubMed
12.
Cook-Bruns N: Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology. 2001, 61 Suppl 2: 58-66.CrossRefPubMed
13.
Chen VW, Ruiz B, Killeen JL, Cote TR, Wu XC, Correa CN: Pathology and classification of ovarian tumors. Cancer. 2003, 97 (10 Suppl): 2631-2642.CrossRefPubMed
14.
Rabassa ME, Croce MV, Pereyra A, Segal-Eiras A: MUC1 expression and anti-MUC1 serum immune response in head and neck squamous cell carcinoma (HNSCC): a multivariate analysis. BMC Cancer. 2006, 6: 253-CrossRefPubMedPubMedCentral
15.
Lambeck A, Leffers N, Hoogeboom BN, Sluiter W, Hamming I, Klip H, ten Hoor K, Esajas M, van Oven M, Drijfhout JW, Platteel I, Offringa R, Hollema H, Melief K, van der Burg S, van der Zee A, Daemen T, Nijman H: P53-specific T cell responses in patients with malignant and benign ovarian tumors: implications for p53 based immunotherapy. Int J Cancer. 2007, 121 (3): 606-614.CrossRefPubMed
16.
Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L: Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007, 7 (2): 95-106.CrossRefPubMed
17.
Trakht I: Development of human monoclonal antibodies and uses thereof. 2001, The Trustees of Columbia University in the City of New York (New York,NY), 040833:
18.
Toubi E, Shoenfeld Y: Protective autoimmunity in cancer (review). Oncol Rep. 2007, 17 (1): 245-251.PubMed
19.
Chen YT: Cancer vaccine: identification of human tumor antigens by SEREX. Cancer JSciAm. 2000, 6 Suppl 3: S208-S217.
20.
Pfreundschuh M: Exploitation of the B cell repertoire for the identification of human tumor antigens. Cancer ChemotherPharmacol. 2000, 46 Suppl: S3-S7.
21.
Scanlan MJ, Gordan JD, Williamson B, Stockert E, Bander NH, Jongeneel V, Gure AO, Jager D, Jager E, Knuth A, Chen YT, Old LJ: Antigens recognized by autologous antibody in patients with renal-cell carcinoma. Int J Cancer. 1999, 83 (4): 456-464.CrossRefPubMed
22.
Tureci O, Sahin U, Zwick C, Neumann F, Pfreundschuh M: Exploitation of the antibody repertoire of cancer patients for the identification of human tumor antigens. Hybridoma. 1999, 18 (1): 23-28.CrossRefPubMed
23.
Kuboshima M, Shimada H, Liu TL, Nakashima K, Nomura F, Takiguchi M, Hiwasa T, Ochiai T: Identification of a novel SEREX antigen, SLC2A1/GLUT1, in esophageal squamous cell carcinoma. Int J Oncol. 2006, 28 (2): 463-468.PubMed
24.
Kalantarov GF, Rudchenko SA, Lobel L, Trakht I: Development of a fusion partner cell line for efficient production of human monoclonal antibodies from peripheral blood lymphocytes. Hum Antibodies. 2002, 11 (3): 85-96.PubMed
25.
Kirman I, Kalantarov GF, Lobel LI, Hibshoosh H, Estabrook A, Canfield R, Trakht I: Isolation of native human monoclonal autoantibodies to breast cancer. Hybrid Hybridomics. 2002, 21 (6): 405-414.CrossRefPubMed
26.
Salama O, Herrmann S, Tziknovsky A, Piura B, Meirovich M, Trakht I, Reed B, Lobel LI, Marks RS: Chemiluminescent optical fiber immunosensor for detection of autoantibodies to ovarian and breast cancer-associated antigens. Biosens Bioelectron. 2007, 22 (7): 1508-1516.CrossRefPubMed
27.
Morrissey JH: Silver stain for proteins in polyacrylamide gels: a modified procedure with enhanced uniform sensitivity. Anal Biochem. 1981, 117 (2): 307-310.CrossRefPubMed
28.
Towbin H, Staehelin T, Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979, 76 (9): 4350-4354.CrossRefPubMedPubMedCentral
29.
Burnette WN: "Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate--polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal Biochem. 1981, 112 (2): 195-203.CrossRefPubMed
30.
Woltanski KP, Besch W, Keilacker H, Ziegler M, Kohnert KD: Radioiodination of peptide hormones and immunoglobulin preparations: comparison of the chloramine T and iodogen method. Exp Clin Endocrinol. 1990, 95 (1): 39-46.CrossRefPubMed
31.
Bobrovnik SA: Ligand-receptor interaction. Klotz-Hunston problem for two classes of binding sites and its solution. J Biochem Biophys Methods. 2002, 52 (2): 135-143.CrossRefPubMed
32.
33.
Scatchard G: The attraction of proteins for small molecule ions. AnnNYAcadSci. 1949, 51: 660-672.CrossRef
34.
Scanlan MJ, Chen YT, Williamson B, Gure AO, Stockert E, Gordan JD, Tureci O, Sahin U, Pfreundschuh M, Old LJ: Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer. 1998, 76 (5): 652-658.CrossRefPubMed
35.
Su ZZ, Shen R, O'Brian CA, Fisher PB: Induction of transformation progression in type 5 adenovirus-transformed rat embryo cells by a cloned protein kinase C beta 1 gene and reversal of progression by 5-azacytidine. Oncogene. 1994, 9 (4): 1123-1132.PubMed
36.
Su ZZ, Shi Y, Fisher PB: Subtraction hybridization identifies a transformation progression-associated gene PEG-3 with sequence homology to a growth arrest and DNA damage-inducible gene. Proc Natl Acad Sci U S A. 1997, 94 (17): 9125-9130.CrossRefPubMedPubMedCentral
37.
Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ: Basic local alignment search tool. J Mol Biol. 1990, 215 (3): 403-410.CrossRefPubMed
38.
De Vries L, Lou X, Zhao G, Zheng B, Farquhar MG: GIPC, a PDZ domain containing protein, interacts specifically with the C terminus of RGS-GAIP. ProcNatlAcadSciUSA. 1998, 95 (21): 12340-12345.CrossRef
39.
Lou X, Yano H, Lee F, Chao MV, Farquhar MG: GIPC and GAIP form a complex with TrkA: a putative link between G protein and receptor tyrosine kinase pathways. MolBiolCell. 2001, 12 (3): 615-627.
40.
De Vries L, Elenko E, Hubler L, Jones TL, Farquhar MG: GAIP is membrane-anchored by palmitoylation and interacts with the activated (GTP-bound) form of G alpha i subunits. Proc Natl Acad Sci U S A. 1996, 93 (26): 15203-15208.CrossRefPubMedPubMedCentral
41.
De Vries L, Elenko E, McCaffery JM, Fischer T, Hubler L, McQuistan T, Watson N, Farquhar MG: RGS-GAIP, a GTPase-activating protein for Galphai heterotrimeric G proteins, is located on clathrin-coated vesicles. Mol Biol Cell. 1998, 9 (5): 1123-1134.CrossRefPubMedPubMedCentral
42.
Vries D: GAIP is membrane-anchored by palmitoylation and interacts with the activated (GTP-bound) form of G alpha i subunits. Proc Natl Acad Sci U S A. 1996, 93: pp. 15203-15208.CrossRef
43.
Lou X, McQuistan T, Orlando RA, Farquhar MG: GAIP, GIPC and Galphai3 are Concentrated in Endocytic Compartments of Proximal Tubule Cells: Putative Role in Regulating Megalin's Function. J Am Soc Nephrol. 2002, 13 (4): 918-927.PubMed
44.
Sattar AA, Boinpally R, Stromer MH, Jena BP: G(alpha)(i3) in pancreatic zymogen granules participates in vesicular fusion. J Biochem. 2002, 131 (6): 815-820.CrossRefPubMed
45.
Wylie F, Heimann K, Le TL, Brown D, Rabnott G, Stow JL: GAIP, a Galphai-3-binding protein, is associated with Golgi-derived vesicles and protein trafficking. Am J Physiol. 1999, 276 (2 Pt 1): C497-C506.PubMed
46.
Kedlaya RH, Bhat KM, Mitchell J, Darnell SJ, Setaluri V: TRP1 interacting PDZ-domain protein GIPC forms oligomers and is localized to intracellular vesicles in human melanocytes. Arch Biochem Biophys. 2006, 454 (2): 160-169.CrossRefPubMedPubMedCentral
47.
Yi Z, Petralia RS, Fu Z, Swanwick CC, Wang YX, Prybylowski K, Sans N, Vicini S, Wenthold RJ: The role of the PDZ protein GIPC in regulating NMDA receptor trafficking. J Neurosci. 2007, 27 (43): 11663-11675.CrossRefPubMed
48.
Muders MH, Dutta SK, Wang L, Lau JS, Bhattacharya R, Smyrk TC, Chari ST, Datta K, Mukhopadhyay D: Expression and regulatory role of GAIP-interacting protein GIPC in pancreatic adenocarcinoma. Cancer Res. 2006, 66 (21): 10264-10268.CrossRefPubMed
49.
Varsano T, Dong MQ, Niesman I, Gacula H, Lou X, Ma T, Testa JR, Yates JR, Farquhar MG: GIPC is recruited by APPL to peripheral TrkA endosomes and regulates TrkA trafficking and signaling. Mol Cell Biol. 2006, 26 (23): 8942-8952.CrossRefPubMedPubMedCentral
50.
Naccache SN, Hasson T, Horowitz A: Binding of internalized receptors to the PDZ domain of GIPC/synectin recruits myosin VI to endocytic vesicles. Proc Natl Acad Sci U S A. 2006, 103 (34): 12735-12740.CrossRefPubMedPubMedCentral
51.
Nunn C, Mao H, Chidiac P, Albert PR: RGS17/RGSZ2 and the RZ/A family of regulators of G-protein signaling. Semin Cell Dev Biol. 2006, 17 (3): 390-399.CrossRefPubMed
52.
Wang L, Mukhopadhyay D, Xu X: C terminus of RGS-GAIP-interacting protein conveys neuropilin-1-mediated signaling during angiogenesis. Faseb J. 2006, 20 (9): 1513-1515.CrossRefPubMed
53.
Abramow-Newerly M, Roy AA, Nunn C, Chidiac P: RGS proteins have a signalling complex: interactions between RGS proteins and GPCRs, effectors, and auxiliary proteins. Cell Signal. 2006, 18 (5): 579-591.CrossRefPubMed
54.
Awan A, Lucic MR, Shaw DM, Sheppard F, Westwater C, Lyons SA, Stern PL: 5T4 interacts with TIP-2/GIPC, a PDZ protein, with implications for metastasis. Biochem Biophys Res Commun. 2002, 290 (3): 1030-1036.CrossRefPubMed
55.
Katoh M: GIPC gene family (Review). Int J Mol Med. 2002, 9 (6): 585-589.PubMed
56.
Liaoyuan: GIPC Interacts with the 1-Adrenergic Receptor andRegulates 1-Adrenergic Receptor-mediated ERK Activation. The Journal Of Biological Chemistry. 2003, 278, No 28 (July 11): 26295-26301.
57.
Bunn RC, Jensen MA, Reed BC: Protein interactions with the glucose transporter binding protein GLUT1CBP that provide a link between GLUT1 and the cytoskeleton. Mol Biol Cell. 1999, 10 (4): 819-832.CrossRefPubMedPubMedCentral
58.
Wang LH, Kalb RG, Strittmatter SM: A PDZ protein regulates the distribution of the transmembrane semaphorin, M-SemF. J Biol Chem. 1999, 274 (20): 14137-14146.CrossRefPubMed
59.
Chang HR, Koda K, Chang S, Baird S: AgSK1, a novel carcinoma associated antigen. Cancer Res. 1993, 53 (5): 1122-1127.PubMed
60.
Koda K, Nakajima N, Saito N, Yasutomi J, McKnight ME, Glassy MC: A human natural antibody to adenocarcinoma that inhibits tumour cell migration. Br J Cancer. 1998, 78 (10): 1313-1322.CrossRefPubMedPubMedCentral
Metadata
Title
A human monoclonal autoantibody to breast cancer identifies the PDZ domain containing protein GIPC1 as a novel breast cancer-associated antigen
Authors
Sergei Rudchenko
Matthew Scanlan
Gavreel Kalantarov
Victoria Yavelsky
Chen Levy
Alison Estabrook
Lloyd Old
Gerald L Chan
Leslie Lobel
Ilya Trakht
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2008
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-8-248

Other articles of this Issue 1/2008

BMC Cancer 1/2008 Go to the issue

Research article

Increase in mammography detected breast cancer over time at a community based regional cancer center: a longitudinal cohort study 1990–2005

Research article

The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells

Research article

Increased expression of EphA7 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients

Research article

Induction of maturation and activation of human dendritic cells: A mechanism underlying the beneficial effect of Viscum albumas complimentary therapy in cancer

Research article

Role of cAMP in the promotion of colorectal cancer cell growth by Prostaglandin E2

Research article

Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits